Cranbury, N.J. and Bengaluru, India: Biopharmaceutical company Biocon Limited (BSE: 532523, NSE: BIOCON) has officially inaugurated its first Biocon US Manufacturing Facility in Cranbury, New Jersey.
The milestone was marked by the presence of New Jersey Governor Phil Murphy, Biocon Chairperson Kiran Mazumdar-Shaw, along with industry leaders, partners, and customers.
Biocon US Manufacturing Facility: Strategic Investment in Cranbury
The new Biocon US Manufacturing Facility was acquired from Eywa Pharma Inc. in 2023 and has since been transformed into a state-of-the-art Oral Solid Dosage (OSD) plant.
Also Read: NIAB Hyderabad Launches Animal Stem Cell BioBank and Laboratory to Boost Veterinary Research
With an investment exceeding USD 30 million, the facility now has an annual capacity of producing 2 billion tablets. Some products have already been launched from the site, with additional therapies in development.
This expansion marks a key step in diversifying Biocon’s manufacturing base and strengthening its supply chain. The facility is designed to ensure faster access to essential medicines, increase supply reliability, and foster stronger connections with U.S. healthcare providers and patients.
Kiran Mazumdar-Shaw, Chairperson of Biocon Group, stated: “Biocon’s first U.S. FDA-approved formulations facility in New Jersey represents a new chapter in our global journey. It not only reflects our long-term commitment to patients but also reinforces our engagement with healthcare providers and communities in the U.S. Governor Murphy’s presence underscores the significance of this milestone for innovation and job creation.”
Also Read: AI in Biopharma: ThinkBio Ai and UST Launch Strategic Alliance
Siddharth Mittal, CEO & MD of Biocon Ltd, added: “The Biocon US Manufacturing Facility strengthens our ability to deliver high-quality, affordable medicines more efficiently. Being closer to patients and healthcare providers in the U.S. ensures resilient supply chains and expands access to therapies worldwide.”
Governor Phil Murphy commented: “We are proud to welcome Biocon’s first U.S. manufacturing facility to New Jersey. This investment reaffirms our state’s reputation as a global hub for pharmaceuticals and strengthens our role as the ‘medicine chest to the world’.”
